Login to Your Account

At Milestone's Peril

Reata's $400M from Abbott Shows Up-Front Trend in 2011

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, January 9, 2012

Last month, Reata Pharmaceuticals Inc. snagged $400 million from Abbott for half of its second-generation antioxidant inflammation modulator (AIM) portfolio, bucking a trend over the last few years of putting the risk on the innovator through milestone payments. (See BioWorld Today, Dec. 13, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription